ALDX — Aldeyra Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1341235 ·
Last close
$1.21
Market Cap
$72.69M
52W High
$5.93
52W Low
$1.07
ADV30
670,230
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,850,507 | -5,450,273 | 47,540,559 | 45,089,786 | 9,655,256 |
| Mar 2026 | 0 | — | -3,546,918 | -3,452,619 | 66,483,081 | 65,002,305 | 24,326,289 |
| Dec 2025 | 0 | — | -6,667,883 | -6,461,507 | 72,059,317 | 70,041,254 | 27,808,927 |
| Sep 2025 | 0 | — | -8,001,132 | -7,688,341 | 77,801,012 | 59,340,599 | 28,556,469 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,020,272
Investing CF
$40,976,903
Financing CF
$-15,108,114
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-492,860,145
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-21,632,877
Pretax Income TTM
$-23,052,740
Interest Exp TTM
$1,419,863
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -35,265,206 | -33,846,661 | 72,059,317 | 27,808,927 | 44,250,390 | -33,345,682 |
| Dec 2024 | 0 | -60,117,032 | -55,851,444 | 104,606,694 | 33,601,823 | 71,004,871 | -43,208,747 |
| Dec 2023 | 0 | -42,794,083 | -37,542,510 | 148,326,911 | 28,531,881 | 119,795,030 | -30,326,128 |
| Dec 2022 | 0 | -62,679,987 | -62,024,636 | 181,291,657 | 30,283,628 | 151,008,029 | -56,637,187 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$981,487
NetIncome TTM
$-9,929,501
OpCashFlow TTM
$0
Assets (Latest)
$72,059,317
Forward EPS
$-0.28
Max Pain — expiry 2026-10-02
max pain strike: $1.00 · spot: $1.17 · call oi: 1,550 · put oi: 7Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MAIA | MAIA Biotechnology, Inc. | $73.00M | $1.20 | — |
| SPRO | Spero Therapeutics, Inc. | $71.63M | $1.23 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $71.10M | $1.33 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $75.07M | $4.37 | — |
| CING | Cingulate Inc. | $70.24M | $4.83 | — |
News headlines (Yahoo Finance, 1h cache)
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
2026-09-25 15:02 · Yahoo
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
2026-09-24 15:50 · Yahoo
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
2026-09-24 13:35 · Yahoo
Vertex Posts Positive Phase II Data on Kidney Disease Drug
2026-09-23 16:08 · Yahoo
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
2026-09-23 15:00 · Yahoo
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
2026-09-22 16:17 · Yahoo
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
2026-09-22 15:00 · Yahoo
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
2026-09-21 17:29 · Yahoo
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
2026-09-21 14:59 · Yahoo
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
2026-09-18 16:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.